Clinical Effectiveness Of Tildipirosin Injectable Solution For The Treatment Of Naturally Occurring Swine Respiratory Disease

Tildipirosin belongs to the sixteen membered ring macrolide semi-synthetic antibiotic.The Tildipirosin Injectable Solution of Intervet,Inc.（trade name of Zuprevo）approved by the European Commission（CVMP）in March 8th,2011.It has been authorized in the USA and Europe,applying for the treatment of swine and bovine respiratory disease caused by Pasteurellamultocida,Haemophilusparasuis,Actinobacilluspleuropneumoniae,Bordetella bronchiseptica and other sensitive bacteria.The clinical effectiveness studies of Tildipirosin for swine respiratory diseases was carried out,following"the Guidelines of Antibacterial Drugs for the Clinical Efficacy Evaluation Phase Ⅱ and Ⅲ"and"GFI#178 Recommended Study Design and Evaluation of Effectiveness Studies for Swine Respiratory Disease Claims".The test agent was Tildipirosin injectable solution and the control agent was Tulathromycin injectable solution（Draxxin?,Zoetis Inc.）.In this study,180 pigs suspected with respiratory diseases were selected as the research animals.The suspected pigs were separated and sampled for laboratory identification.Then the minimum inhibitory concentration（MIC）of Tildipirosin against the main isolates was determined,which showed that the MIC of 39 strains of Actinobacillus pleuropneumoniae was 2³2μg/mL,MIC₅₀ was 4μg/mL,MIC₉₀ was 16μg/mL.The MIC of 74 strains of H.parasuis was 0.06⁸μg/mL,MIC₅₀ was 0.5μg/mL,MIC₉₀ was 2μg/mL.The MIC of 25 strains of Pasteurella multocida was 0.25¹μg/mL,MIC₅₀ was 0.5μg/mL,MIC₉₀ was 1μg/mL;The MIC of 10 strains Bordetella bronchiseptica was 0.06⁸μg/mL,MIC₅₀ was 2μg/mL,MIC₉₀ was 8μg/mL.It indicated that Tildipirosin had a better antibacterial activity against the main pathogenic bacteria isolated.According to the identification results of pathogenic bacteria,138 pigs infected with porcine respiratory diseases were selected as experimental animals.Transform procedure of IBM SPSS Statistics Version 21 was used for dividing the animals into two groups randomly including the test group and the control group,with 69 animals in each group,respectively.The test group was treated with Tildipirosin Injectable Solution and the control group was treated with Tulathromycin injectable solution.The results indicated that both drugs have a good therapeutic effect after administration.The body temperature of the animals returned to normal,and the clinical symptoms such as cough and mental deterioration disappeared too.Meanwhile,the pathogens in the sick animals could be effectively eliminated.The effective rate,cure rate and mortality rate were analyzed by using the Chi-square test.Based on the results of these studies,there is no significant difference between the Tildipirosin-treated group and the Tulathromycin-treated group（X²=3.84,P>0.05）.At14th day after administration,the effective rate of the two groups were 86.96%and 84.06%respectively,and the cure rate were 82.61%and 81.16%respectively,indicating that both groups had the equivalent effect.The results of this study demonstrate that the Tildipirosin Injectable Solution administered at a clinical recommended dosage of 4 mg/kg BW,is effective for the control of swine respiratory disease associated with Haemophilus parasuis,Pasteurella multocida,Actinobacillus pleuropneumoniae and Bordetella bronchiseptica.